How technology and requirements of plant design were brought in line with shareholder value. Paul Coleman, Biogen Idec's European Manufacturing Site Manager candidly recounts up's and down's of launching a biodrug, re-locating a plant, operative consequences of a merger, and recovering from the sudden withdrawal of Tysabri.

To access this article, please click on your left "Subscription". Thank you.